Abstract

Many publications have clearly demonstrated positive immunological effects and clinical efficacy of allergen immunotherapy (AIT) in allergic rhinitis (AR)/rhinoconjunctivitis and asthma due to many allergens. Other demonstrated effects of AIT in allergic respiratory diseases include long-lasting efficacy and the prevention of progression of AR to asthma. AIT is currently restricted to carefully selected patients with AR who are unresponsive to appropriate pharmacotherapy and HDM‐driven allergic asthma. Due to its preventive and long-term effects, AIT should be probably considered early in patients with persistent AR and asthma, following proper diagnosis and cost-benefit evaluation, in order to inhibit the progression of the allergic inflammation to airway remodeling and to reduce the amount of drugs needed. 

 

References

  1. Brozek JL, Bousquet J, Agache J, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines – 2016 revision. Allergy Clin Immunol 2017;140:950-958. https://doi.org/10.1016/j.jaci.2017.03.050.
  2. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2024 Updated May 2024. https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf.
  3. Curtis HH. The immunizing cure of hay fever. NY Med J 1900;77:16-18.
  4. Noon L, Cantar B. Prophylactic Inoculation against Hay Fever. Lancet 1911;177:1572-1573.
  5. Calderon MA, Casale TB, Nelson HS, et al. Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United States. J Allergy Clin Immunol Pract 2023;11:1100-1115. https://doi.org/10.1016/j.jaip.2022.10.033.
  6. Fiala S and Fleit HB. Clinical and experimental treatment of allergic asthmawith an emphasis on allergen immunotherapy and its mechanisms.Clin Exp Immunol2023;212:14-28. https://doi.org/10.1093/cei/uxad031.
  7. Roberts G, Pfaar O, Akdis A, et al. EAACI Guidelines on Allergen Immunotherapy: allergic rhinoconjunctivitis. Allergy 2018;73:765-798. https://doi.org/10.1111/all.13317.
  8. Batard T, Taillé C, Guilleminault L, et al, Allergen Immunotherapy for the Prevention and Treatment. Clin Exp Allergy 2025;55:111-141. https://doi.org/10.1111/cea.14575.
  9. Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clin Transl Allergy 2017;7:24. https://doi.org/10.1186/s13601-017-0159-6.
  10. Rice JL, Diette GB, Suarez-Cuervo C, et al. Allergen-Specific Immunotherapy in the Treatment of Pediatric Asthma: a Systematic Review. Pediatrics 2018;141:e20173833. https://doi.org/10.1542/peds.2017-3833.
  11. Yang W, Wang W, Ji Y, et al. Efficacy and safety of subcutaneous and sublingual allergen immunotherapy in the treatment of asthma in children: a systematic review and meta-analysis. J Asthma 2025;62:124-133. https://doi.org/10.1080/02770903.2024.2391441.
  12. Bousquet J, Pfaar O, Agache I, et al. ARIA-EAACI care pathways for allergen immunotherapy in respiratory allergy. Clin Transl Allergy. 2021;11:e12014. https://doi.org/10.1002/clt2.12014
  13. Muraro A, Roberts G, Halken S, et al. EAACI guidelines on allergen immunotherapy: Executive statement. Allergy 2018;73:739-743. https://doi.org/10.1111/all.
  14. Jacobsen L, Niggemann B, Dreborg S, et al.; The PAT investigator group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943-948. https://doi.org/10.1111/j.1398-9995.2007.01451.x.
  15. Durham SR, Emminger W, Kapp A, et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in randomizeded trial. J Allergy Clin Immunol 2012;129:717-725.e5. https://doi.org/10.1016/j.jaci.2011.12.973.
  16. Yonekura S, Gotoh M, Kaneko S, et al. Disease-Modifying Effect of Japanese Cedar Pollen Sublingual Immunotherapy Tablets. J Allergy Clin Immunol Pract 2021;9:4103-4116.e14. https://doi.org/.1016/j.jaip.2021.06.060.
  17. Contoli M, Porsbjerg C, Buchs S, et al. Real-world, long-term effectiveness of allergy immunotherapy in allergic rhinitis: Subgroup analyses of the REACT study. J Allergy Clin Immunol 2023;152:445-452.e4. https://doi.org/10.1016/j.jaci.2023.02.024.
  18. Des Roches A, Paradis L, Menardo JL. Immunotherapy with standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol 1997;99:450-453. https://doi.org/10.1016/s0091-6749(97)70069-1.
  19. Pajno GB, Barberio G, De Luca F, et al. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392-1397. https://doi.org/10.1046/j.1365-2222.2001.01161.x.
  20. Marogna M, Tomassetti D, Bernasconi A, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomizeded controlled study. Ann Allergy Asthma Immunol 2008;101:206-211. https://doi.org/10.1016/s1081-1206(10)60211-6.
  21. Dwivedi V, Kopanja S, Schmidthaler K, et al. Preventive allergen immunotherapy with inhalant allergens in children. Allergy 2024;79:2065-2087. https://doi.org/10.1111/all.16115.
  22. Di Lorenzo G, Leto-Barone MS, La Piana S, et al.. The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis. Int Forum Allergy Rhinol 2017;7:660-669. https://doi.org/10.1002/alr.21946.
  23. Passalacqua G, Ciprandi G, Canonica GW, et al. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol 2001;1:7-13. https://doi.org/10.1097/01.all.0000010978.62527.4e.
  24. Licari A, Castagnoli R, Denicolò CF, et al. The Nose and the Lung: United Airway Disease? Front Pediatr 2017;5:44. https://doi.org/10.3389/fped.2017.00044.
  25. Cruz AA, Popov T, Pawankar R, et al.; ARIA Initiative Scientific Committee. Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN. Allergy 2007;62(Suppl 84):1-41. https://doi.org/10.1111/j.1398-9995.2007.01551.x.
  26. Lindqvist M, Leth-Møller KB, Linneberg A, et al. Natural course of pollen-induced allergic rhinitis from childhood to adulthood: a 20-year follow up. Allergy 2024;79:884-893. https://doi.org/10.1111/all.1592713989995, 2024.
  27. Xu X, Yin J, Yang Y, et al. Advances in co-pathogenesis of the united airway diseases. Respir Med 2024;225:107580. https://doi.org/10.1016/j.rmed.2024.107580.
  28. Siroux V, Ballardini N, Soler M, et al. The asthma-rhinitis multimorbidity is associated with polysensitizations in adolescents and adults. Allergy 2018;73:1447-1458. https://doi.org/10.1111/all.13410.
  29. Toppila-Salmi S, Chanoine S, Karjalainen J, et al. Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age. Allergy 2019;74:2406-2416. https://doi.org/10.1111/all.13971.
  30. Bousquet J, Melén E, Haahtela T, et al. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis. Allergy 2023;78:1169-1203. https://doi.org/10.1111/all.15679.
  31. Wahn U. Preventing new sensitizations and asthma onset by allergen immunotherapy: the current evidence. Curr Opin Allergy Clin Immunol 2017;17:443-446, https://doi.org/10.1097/ACI.0000000000000399.
  32. Kristiansen M, Dhami S, Netuveli G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis Pediatr Allergy Immunol 2017;28:18-29. https://doi.org/10.1111/pai.12661.
  33. Gradman, S, Halken S. Preventive Effect of Allergen Immunotherapy on Asthma and New Sensitizations. J Allergy Clin Immunol Pract 2021;9:1813-1817. https://doi.org/10.1016/j.jaip.2021.03.010.
  34. Möller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251-256. https://doi.org/10.1067/mai.2002.121317.
  35. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851-857. https://doi.org/10.1016/j.jaci.2004.07.012.
  36. Valovirta E, Petersen TH, Piotrowska T, et al; GAP investigators. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol 2018;141:529-538.e13. https://doi.org/10.1016/j.jaci.2017.06.014.
  37. Devillier P, Demoly P, Molimard M. Allergen immunotherapy: what is the added value of real-world evidence from retrospective claims database studies? Expert Rev Respir Med 2020;14:445-452. https://doi.org/10.1080/17476348.2020.1733417.
  38. Farraia M, Paciência I, Castro Mendes F, et al. Allergen immunotherapy for asthma prevention: a systematic review and meta-analysis randomized and non-randomized controlled studies. Allergy 2022;77:1719-1735. https://doi.org/10.1111/all.15295.
  39. Torres MI, Gil-Mata S, Bognanni A, et al. Allergic Rhinitis and its Impact on Asthma 2024 Guideline Panel. Intranasal Versus Oral Treatments for Allergic Rhinitis: a Systematic Review With Meta-Analysis. J Allergy Clin Immunol Pract 2024;12:3404-3418. https://doi.org/10.1016/j.jaip.2024.09.001.
  40. Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy 2019;74:855-873. https://doi.org/10.1111/all.13749.
  41. Schmitt J, Wüstenberg E, Küster D, et al. The moderating role ofallergy immunotherapy in asthma progression: Results of a population-based cohort study. Allergy 2020;75:596-602. https://doi.org/10.1111/all.14020.
  42. Guía Española para el Manejo del Asma (GEMA) 2024. Available from: http://www.gemasma.com.
  43. Brusselle GG, Koppelman GH. Biologic Therapies for Severe Asthma. N Engl J Med 202213;386:157-171. https://doi.org/10.1056/NEJMra2032506.
  44. Larenas-Linnemann D, Diamant Z, Jesenak M, et al.Combination of allergen-specific immunotherapy with biologics in severe asthma: contra-intuitive or rational? J Allergy Clin Immunol Pract 2025;13:1581-1596. https://doi.org/10.1016/j.jaip.2025.05.003.
  45. Schuster A, Caimmi D, Nolte H, et al. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet (12 SQ-HDM) in children with allergic rhinitis/rhinoconjunctivitis with or without asthma (MT-12): randomized, double-blind, placebo-controlled, phase III trial. Lancet Reg Health Eur 2024;48:101136. https://doi.org/10.1016/j.lanepe.2024.101136.
  46. Qi S, Chen H, Huang N, et al. Early Intervention Improves Clinical Responses to House Dust Mite Immunotherapy in Allergic Rhinitis Patients. Int Arch Allergy Immunol 2016;171:234-240. https://doi.org/10.1159/000452333.
  47. Sasamoto K, Nagakura KI, Asaumi T, et al. Efficacy and safety of sublingual immunotherapy using house dust mite tablet for 1-4 years old children with perennial allergic rhinitis. Pediatr Allergy Immunol 2024;35:e14203. https://doi.org/10.1111/pai.14203.
  48. Cox L. Pharmacoeconomics of allergy immunotherapy versus pharmacotherapy. Expert Rev Clin Immunol 202;17:255-268. https://doi.org/10.1080/1744666X.2021.1886079.
  49. Rodríguez-Otero N, Ramírez-Mateo E, Plana MN, et al.. Cost-effectiveness of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2024;24:496-503. https://doi.org/10.1097/ACI.0000000000001028.
  50. Novembre E, Barni S, Mori F. The prescriptive paradox of allergen immunotherapy for respiratory allergic diseases. Italian Journal of Pediatric Allergy and Immunology 2024;38:15-18. https://doi.org/10.53151/2531-3916/2024-638.

Downloads

pdf
Authors

Elio Massimo Novembre - Department of Health Sciences, University of Florence, Florence, Italy

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright

Copyright (c) 2025 Italian Journal of Pediatric Allergy and Immunology

How to Cite
Novembre, E. M. (2025). Allergen immunotherapy in allergic rhinitis and asthma. Italian Journal of Pediatric Allergy and Immunology, 39(3). https://doi.org/10.53151/2531-3916/2025-1500
  • Abstract viewed - 83 times
  • pdf downloaded - 18 times